Skip to main content

Animations

MJFF Publications

3971 - 3980 of 8824 Results
Title
Year
  • Year
  • 2019
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • Summary Details
    OPEN
    Title: New transgenic models of Parkinson's disease using genome editing technology
    Journal Name: Neurología (English Edition)
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nrleng.2017.08.006
    Citation Count: 3
  • Summary Details
    RESTRICTED
    Title: Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2020.108386
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.05.047
    Citation Count: 22
  • Summary Details
    RESTRICTED
    Title: Effects of subthalamic nucleus deep brain stimulation on neuronal spiking activity in the substantia nigra pars compacta in a rat model of Parkinson’s disease
    Journal Name: Neuroscience Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neulet.2020.135443
    Citation Count: 11
  • Summary Details
    RESTRICTED
    Title: Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson’s Disease
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.02.046
    Citation Count: 45
  • Summary Details
    OPEN
    Title: The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.027
    Citation Count: 42
  • Summary Details
    OPEN
    Title: Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.04.002
    Citation Count: 55
  • Summary Details
    OPEN
    Title: Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2020.04.032
    Citation Count: 24
  • Summary Details
    RESTRICTED
    Title: GBA variation and susceptibility to multiple system atrophy
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.007
    Citation Count: 25
  • Summary Details
    RESTRICTED
    Title: Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.026
    Citation Count: 40
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.